In Brief: Auragen
This article was originally published in The Gray Sheet
Executive Summary
Auragen: W.R. Grace & Co. subsidiary awarded $960,000 three-year research grant from U.S. Army Medical Research and Material Command's Breast Cancer Research Program to evaluate its Accell gene therapy system for breast cancer. The grant allows the Middleton, Wisconsin-based firm to evaluate the therapeutic potential of using the gene gun device to cutaneously deliver the interleukin-12 gene for mammary tumor therapy in animal models...